Mega Genomics Resultados de beneficios anteriores
Pasado controles de criterios 2/6
Mega Genomics's earnings have been declining at an average annual rate of -29.3%, while the Healthcare industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 8.7% per year. Mega Genomics's return on equity is 4.8%, and it has net margins of 20%.
Información clave
-29.3%
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de la industria Healthcare | 11.3% |
| Tasa de crecimiento de los ingresos | 8.7% |
| Rentabilidad financiera | 4.8% |
| Margen neto | 20.0% |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Shareholders Will Be Pleased With The Quality of Mega Genomics' (HKG:6667) Earnings
Oct 03
Returns On Capital Signal Tricky Times Ahead For Mega Genomics (HKG:6667)
Aug 28Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Calculating The Intrinsic Value Of Mega Genomics Limited (HKG:6667)
Feb 20Mega Genomics Limited's (HKG:6667) Share Price Could Signal Some Risk
Aug 12A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)
Nov 07Desglose de ingresos y gastos
Cómo gana y gasta dinero Mega Genomics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 160 | 32 | 59 | 0 |
| 31 Mar 24 | 156 | 31 | 60 | 0 |
| 31 Dec 23 | 151 | 30 | 61 | 0 |
| 30 Sep 23 | 149 | 15 | 82 | 0 |
| 30 Jun 23 | 147 | 0 | 103 | 0 |
| 31 Mar 23 | 146 | -9 | 103 | 0 |
| 31 Dec 22 | 146 | -18 | 104 | 0 |
| 30 Sep 22 | 192 | 22 | 84 | 0 |
| 30 Jun 22 | 238 | 62 | 65 | 0 |
| 31 Mar 22 | 238 | 70 | 58 | 0 |
| 31 Dec 21 | 237 | 79 | 52 | 0 |
| 31 Dec 20 | 203 | 79 | 35 | 0 |
| 31 Dec 19 | 124 | 30 | 27 | 0 |
Ingresos de calidad: 6667 has high quality earnings.
Margen de beneficios creciente: 6667 became profitable in the past.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: 6667's earnings have declined by 29.3% per year over the past 5 years.
Acelerando crecimiento: 6667 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Beneficios vs. Industria: 6667 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (-16.9%).
Rentabilidad financiera
Alta ROE: 6667's Return on Equity (4.8%) is considered low.